The correct name for mannitol is Mannitol Injection. It is contraindicated in the following patients: anuric patients who have been diagnosed with acute tubular necrosis, including those who do not respond to the use of mannitol, those with severe water loss, those with active intracranial hemorrhage, and those with acute pulmonary edema or severe pulmonary bruising. Mannitol Injection is used as a dehydrating agent for the treatment of cerebral edema, lowering intracranial pressure, preventing cerebral herniation, and lowering intraocular pressure; as a diuretic for low urine output, prevention of acute tubular necrosis, nephrotic syndrome, and ascites in cirrhosis of the liver; as an overdose or toxicity promoter of excretion of certain medications to prevent nephrotoxicity; as a flushing agent in transurethral endobaric resection of the prostate; and in preoperative bowel preparation. Mannitol injection may have water and electrolyte disorders, hyponatremia, hyperkalemia, aggravated oliguria, tissue dehydration, chills, fever, dysuria, thrombophlebitis, edema, rash, urticaria, dyspnea, dizziness, and thirst, and other adverse reactions. Mannitol Injection should be used with caution in persons with significant cardiopulmonary impairment, hypovolemia, severe renal failure, and intolerance to mannitol. If you need to use please consult a professional doctor, with the help and guidance of the doctor to follow the doctor’s instructions to inject the drug.